Company ProfilePremium

Echo IQ Limited (formerly Houston We Have Limited)

Company Profile Analysis

Ticker: EIQ.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Echo IQ Limited - Company showcase

Year Founded & Workforce

2010

2,590,000 Employees

Echo IQ Limited logo

Echo IQ Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Echo IQ Limited Overview

Echo IQ Limited is an ASX-listed artificial intelligence and medical technology company. It applies machine learning to routinely acquired echocardiography measurements to help cardiologists detect structural heart disease and heart failure. The company describes itself as using "AI-driven technology and proprietary software to improve decision making in cardiology."

Its flagship product, EchoSolv AS, received US FDA 510(k) clearance for detecting severe aortic stenosis in late 2024. It is deployed at Beth Israel Deaconess Medical Center and the Mount Sinai Health System. Its second product, EchoSolv HF for heart failure, received an FDA "Not Substantially Equivalent" determination in September 2026. The company is pursuing an appeal, an Ombudsman review or a resubmission.

Echo IQ is pre-revenue in practice: FY2026 revenue was A$91.6k against a net loss of A$18.6m. However, it is well funded after a A$110m placement in July 2026. It is building a US land-and-expand commercial model through direct sales and partners such as Pro Medicus, the Mayo Clinic Platform, ScImage and SARC MedIQ.


Company's own description (FY2026 Annual Report, paraphrased)

The FY2026 Annual Report describes Echo IQ as an AI and medical technology company focused on improving decision making in cardiology. Its proprietary EchoSolv platform applies AI and machine learning to routinely acquired echocardiographic data. The goal is to help clinicians identify and assess structural heart disease and other cardiovascular conditions.

The directors' report defines the group's principal activity as the development and application of AI for the cardiac diagnostics sector. The FY2026 segment note widens the development scope beyond aortic stenosis. It now includes heart failure, pulmonary hypertension, hypertrophic cardiomyopathy, mitral regurgitation and cardio-oncology.

Independent characterisation

Echo IQ is best understood as an early-commercial, venture-stage clinical decision support software company. Its technology does not interpret echo images directly. Instead, it ingests the structured measurement set already recorded in a standard echocardiography report (more than 140 measurements, according to Stockhead's description of EchoSolv HF). It then produces a disease-likelihood score.

This design has three consequences:

Integration is light: The software sits downstream of existing echo reporting systems and PACS (picture archiving) workflows.

Training data is scalable: The core asset is exclusive access to the National Echo Database of Australia (NEDA), which links echo measurements to patient outcomes. It is now supplemented by up to one million studies licensed from Advara HeartCare.

Regulatory exposure is concentrated: Each new indication needs its own FDA clearance. The September 2026 heart-failure determination shows that regulatory risk falls on the predicate-device argument, not just on clinical performance.

Business model and revenue model

DimensionCharacterisationEvidence
Product vs service mixSoftware as a medical device (SaMD), licensed per scan or by enterprise contractFY2025 AR: SARC MedIQ pays per scan; Miscellaneous Code 93799 is used fee-per-use
Subscription / licensingEmerging enterprise contracts (VIEW and SHADOW evaluation programs leading to full deployment)FY2026 AR: three enterprise proposals covering 300+ hospitals
Reimbursement-linked revenueUS$100–150 per use under Miscellaneous Code 93799, with Echo IQ receiving 30–60% of total reimbursementFY2025 AR
Data and research revenueFunded pilots and trials, such as an Australia/New Zealand structural-heart device company pilot and the Edwards Lifesciences-funded aortic stenosis trial in 2021FY2025 AR; Stockhead 2021
Revenue recognisedA$91.6k in FY2026, all from Australia except A$1k from the US. Customer cash receipts were nil.FY2026 AR, Note 4 and segment note

Value chain position

Echo IQ sits at the clinical-interpretation layer of the cardiac imaging chain:

  1. Echo acquisition, using hardware from GE HealthCare, Philips, Siemens Healthineers and others.

  2. Measurement and reporting, using cardiology PACS and structured reporting from vendors such as ScImage, SARC MedIQ and Pro Medicus Visage 7 Cardiology.

  3. EchoSolv AI decision support, which flags at-risk patients.

  4. Referral to treatment, such as transcatheter aortic valve replacement or heart-failure therapy.

The downstream link matters. Diagnosing more severe aortic stenosis drives valve-replacement procedures (around US$22,000–28,000 each in the US, per Biotech Daily, November 2024). This is why valve makers such as Edwards Lifesciences have funded the company's evidence generation.

Customer types and end-markets

Hospital systems and academic medical centres (primary): Beth Israel Deaconess Medical Center (Boston) and Mount Sinai Health System (New York). The pipeline exceeds 70 hospitals.

Imaging and PACS channel partners: ScImage/MedAxiom, SARC MedIQ, Pro Medicus (proposed reseller) and the Mayo Clinic Platform Solutions Studio (contingent on heart-failure clearance).

Medical device and pharmaceutical companies: used for patient-finding programs, such as the Australia/New Zealand quality-assurance pilot with an unnamed global structural-heart company.

End-markets: US cardiology (aortic stenosis and heart failure). Australia and New Zealand are pilot markets. Europe, the UK and Australia are flagged as future regulatory pathways in the FY2026 outlook.

Financial Narrative

Basis. Audited figures from the FY2023–FY2026 reports. FY2022 revenue and net loss come from the five-year table in the FY2025/FY2026 remuneration reports. FY2024 figures follow the FY2025 Annual Report restatement where it differs from the unaudited FY2024 Appendix 4E (differences are noted). FY2026 is reported in A$ thousands.

Income statement

Calculation notes:

Gross profit: no cost-of-sales line is disclosed.

EBITDA: pre-tax loss plus D&A. It includes interest income because the company has no finance costs.

FY2023 EPS: total figure (continuing −1.84c; discontinued +0.09c).

Pre-FY2022: FY2021 revenue was A$983.2k and the net loss A$2.99m (FY2025 AR five-year table).

Margins

Revenue CAGR FY2022–FY2026: −43.6% per year (analyst calculation, (91.6/904.1)^(1/4) − 1). This figure is distorted by the exit from the legacy Houston We Have software business. On a like-for-like cardiac-AI basis, revenue has fluctuated between A$45k and A$107k with no compounding trend.

Commentary. Margins are not a useful performance measure here. The figures that matter are:

Cash operating expenses: rose 57% in FY2026 to A$13.75m, led by employee costs (+89%), consulting and professional fees (+42%) and marketing (+186%).

Share-based payments: stayed around A$6.2m for the second year running, about one-third of the reported loss.

Grant income: fell from A$1.95m (FY2024) to A$0.76m (FY2026), so there is less non-dilutive funding to offset spending.

The inflection point is FY2025–FY2026. The company moved from a sub-A$7m cash opex base to a US commercial build, and the loss widened 40% in FY2026 even as utilisation grew.

Balance sheet

FY2022 cash, equity, contributed equity and accumulated losses are the opening balances at 1 July 2022 in the FY2023 statements.

Post-balance-date pro forma (analyst view). The A$110m placement settled on 6–7 July 2026. The company stated cash at bank exceeded A$105m as of July 2026 (Smallcaps, citing the September 2026 announcement). The Pro Medicus convertible notes (A$10m initial) were documented on 17 August 2026. The FY2026 AR states funding remained subject to conditions, including a binding reseller agreement. Whether the notes have been drawn is not publicly confirmed in the documents reviewed. If drawn, gross debt would be A$10m, offset by the equivalent cash.

Cash flow

FY2024 operating cash flow and financing follow the FY2025 AR comparatives (−A$3.924m and A$2.765m). The unaudited FY2024 4E reported −A$4.015m and A$2.855m.

Cash-flow commentary. Customer receipts were nil in FY2026. The A$91.6k of revenue recognised came from releasing a A$100k contract liability (customer prepayment) carried at 30 June 2025, and Börse Express reported no customer revenue for FY2026. Operating cash burn rose 62% to A$10.6m. Quarterly data show acceleration: A$2.51m in the September 2025 quarter and A$5.18m in the December 2025 half.

At a run rate of roughly A$14–20m in FY2027 (analyst assumption, given a ~25% salary uplift and continued US hiring), July 2026 cash of more than A$105m implies a runway well beyond five years before acquisitions. The constraint on the business is commercial traction, not funding.

Ratios

Notes: ROIC is not meaningful (negative operating returns; invested capital is mostly cash and the NEDA intangible). Net debt/EBITDA is not meaningful because of net cash and negative EBITDA. Interest coverage is not meaningful because there is no interest expense. The cash conversion cycle is not meaningful given near-zero revenue and no inventory.

Ratio commentary. Negative ROE above 100% in FY2026 reflects a loss that exceeds the year-end equity base, which had been depleted before the July 2026 raise. Pro forma equity after the raise is roughly A$120m. On that basis, an FY2027 loss of A$20–25m would imply ROE of about −20%.

The current ratio swings with the timing of raises. The balance sheet is debt-free with no covenants, although Note 16 contains generic covenant language. The going-concern material uncertainty flagged at FY2024 has been removed: FY2025 and FY2026 opinions are unmodified.

Half-year and quarterly operating metrics

There is a discrepancy on June-quarter growth. The FY2026 AR cites about 11% quarter-on-quarter growth in echos processed, while Börse Express reported 20%. The raw figures (9,220 to about 10,200) imply about 11%.


7. SEGMENTAL AND GEOGRAPHIC REVENUE MAPPING

Segment-by-geography matrix (FY2026)

Country-level detail beyond the US and Australia is not disclosed. New Zealand pilot activity (part of the Australia/New Zealand structural-heart pilot) and the UK references in third-party profiles are not separately reported.

Fastest-growing and declining regions

Fastest growing (by activity, not revenue): United States: Utilisation is the leading indicator. EchoSolv AS echo volumes grew about 131% quarter-on-quarter in the March 2026 quarter and more than 400% year-on-year in the June 2026 quarter. The US pipeline grew to 70+ hospitals. US revenue has not followed because:

  • The Category III CPT code was rejected in October 2025.

  • Miscellaneous Code 93799 reimbursement is discretionary and slow to collect.

  • Early deployments (VIEW, SHADOW, BIDMC research) are evaluation or research-oriented.

Declining: Australia: Revenue fell 10% in FY2026. Australian revenue is project-based (pilots and trials) and is not expected to scale. Australia is effectively the research and development base and NEDA data centre, not a commercial market.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD K)

904.1107.344.5101.491.6

Revenue growth YoY (%)

—-88.1-58.5127.9-9.6

Other income incl grants and interest (AUD K)

—73.81,996.91,578.91,282

Government grants / R&D incentive (AUD K)

——1,949.61,260.9763

Interest income (AUD K)

——47.3201.9519

Total operating expenses incl SBP (AUD K)

—8,447.07,450.614,942.819,940

Operating expenses excl SBP (AUD K)

—6,066.66,642.38,746.113,750

Share-based payments expense (AUD K)

—2,380.3808.36,196.76,189

Depreciation and amortisation (AUD K)

—607.3603.7577.2549

Operating income / EBIT, continuing (AUD K)

—-8,265.8-5,409.1-13,262.5-18,566

EBITDA (AUD K, analyst calc)

—-7,658.5-4,805.5-12,685.3-18,017

Pre-tax income, continuing (AUD K)

—-8,265.8-5,409.1-13,262.5-18,566

Profit from discontinued operations (AUD K)

—410.2000

Net income (AUD K)

-5,992.0-7,855.6-5,409.1-13,262.5-18,566

EPS basic (A cents)

—-1.75-1.09-2.26-2.84

EPS diluted (A cents)

—-1.75-1.09-2.26-2.84

Dividends per share (A cents)

00000

Weighted average shares (millions)

——497.6585.7652.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Operating margin (%)

—-7,701-12,155-13,079-20,258

EBITDA margin (%)

—-7,137-10,799-12,510-19,659

Net margin (%)

-663-7,319-12,155-13,079-20,258

SBP as % of total operating expenses

—28.210.841.531.0

Expense line (AUD K)

Expense line (AUD K)FY2023FY2024FY2025FY2026

Employee costs (AUD K)

2,586.12,924.33,239.86,113

Consulting and professional fees (AUD K)

1,543.21,657.52,498.53,549

Directors fees (AUD K)

376.7494.9820.5635

Marketing and PR (AUD K)

105.112.8266.7763

Other expenses (AUD K)

664.8804.81,133.71,934

Audit fees (AUD K)

75.869.376.180

Share registry and listing (AUD K)

107.775.1133.6128

Balance Sheet and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents (AUD K)

2,406.93,276.42,117.36,617.78,712

Term deposits (AUD K)

00011,518.30

Total liquidity: cash plus deposits (AUD K)

2,406.93,276.42,117.318,136.08,712

Total current assets (AUD K)

—3,978.02,453.518,645.69,644

Intangible assets incl NEDA (AUD K)

—6,367.05,783.14,686.94,162

Goodwill (AUD K)

—0000

Total assets (AUD K)

—10,383.78,255.623,372.313,875

Total current liabilities (AUD K)

—3,000.91,487.6615.42,246

Short-term debt (AUD K)

—0000

Long-term debt (AUD K)

—0000

Net debt, negative = net cash (AUD K)

-2,406.9-3,276.4-2,117.3-18,136.0-8,712

Total equity (AUD K)

8,020.07,382.86,768.022,756.911,629

Contributed equity (AUD K)

30,400.335,997.441,530.264,618.568,153

Accumulated losses (AUD K)

-27,715.3-35,191.7-39,095.3-49,031.6-65,524

Working capital (AUD K)

—977.1965.918,030.17,398

Shares on issue at year end (millions)

—472.3537.7645.2660.9

NTA per share (A cents)

—0.230.182.801.13

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Receipts from customers (AUD K)

—107.937.5200.00

Operating cash flow (AUD K)

—-4,940.3-3,924.2-6,508.9-10,564

Capex incl intangibles (AUD K)

—-339.70-35.8-53

Free cash flow (AUD K, analyst calc)

—-5,280.0-3,924.2-6,544.7-10,617

Equity raised incl option exercises, net (AUD K)

—5,879.02,765.022,563.41,215

Dividends paid (AUD K)

00000

Share buybacks (AUD K)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

—-102.0-76.5-89.8-108.0

ROA on average assets (%)

——-58.0-83.9-99.7

Current ratio (x)

—1.331.6530.304.29

Debt to equity (x)

00000

Asset turnover (x)

——0.0050.0060.005

Revenue History

PeriodRevenue (AUD)Net loss (AUD)Liquidity at period end (AUD Mn)Echos processedSource

H1 FY2025 (to 31 Dec 2024)

101,409-6,215,6455.35—

H1 FY2026 comparatives

H1 FY2026 (to 31 Dec 2025)

90,909-8,659,66913.21—

H1 FY2026 report

H2 FY2026 (analyst calc)

737-9,906,0868.71—

FY2026 less H1

Sep Q 2025

——15.90

+153% QoQ (integrated US customers)

Q1 FY2026 4C

Dec Q 2025

——13.213,992

FY2026 AR

Mar Q 2026

——11.149,220

FY2026 AR

Jun Q 2026

——8.7110,200

FY2026 AR

Income Statement and Margin Analysis (%) by Region

RegionFY2022FY2023FY2024FY2025FY2026

Australia revenue (AUD K)

——44.5101.491

United States revenue (AUD K)

——001

Total revenue (AUD K)

904.1107.344.5101.491.6

Australia share of revenue (%)

——10010099

United States share of revenue (%)

——001

Region growth (%)

Region growth (%)FY2025 vs FY2024FY2026 vs FY2025

Australia

+128%−10%

United States

n/m (from zero)

n/m (A$1k)

Share Price and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Share price FY high (AUD)

0.190.230.210.361.62

Share price FY low (AUD)

0.100.110.100.140.17

Shares on issue at year end (millions)

—472.3537.7645.2660.9

Equity raised in year incl options (AUD Mn)

—5.92.822.61.2

Share Price & Returns

HorizonPerformanceBasis

Year to date 2026

About +146% (A$0.26 to about A$0.64)

InvestSMART start-of-year price; latest reference price

1 year

About +210% (about A$0.205 on 6 October 2025 to about A$0.64)

Analyst calculation

From peak

About −65% (A$1.875 intraday high to about A$0.64–0.66)

Motley Fool, 23 September 2026

3 year

Not precisely verifiable. The FY2024 trading range of A$0.10–0.21 implies roughly 3–6x.

FY2026 remuneration report

5 year

Not precisely verifiable. The A$0.05 placement price in March 2021 implies more than 10x.

Stockhead 2021

Valuation Snapshot

MetricValueDerivation

Market capitalisation

About A$474m

740.6m shares × A$0.64 (matches the StockLight figure)

Net cash

About A$95–105m

More than A$105m in July 2026, less estimated Q1 FY2027 burn. The September 2026 quarterly 4C was not yet available.

Enterprise value

About A$370–380m

Market cap less net cash

EV / FY2026 sales

About 4,000x

A$375m / A$0.092m

P/E

Not meaningful (loss-making)

—

EV/EBITDA

Not meaningful (negative EBITDA)

—

P/B (reported 30 June 2026 equity A$11.6m)

About 41x

Distorted by the timing of the raise

P/B (pro forma equity about A$120m)

About 4.0x

Adds about A$108m net placement proceeds

Peer multiples

Not computed. Comparable cardiac AI peers are mostly private.

—

Analyst Ratings & Targets

BrokerRatingTarget (AUD)Date / notes

Morgans

Speculative Buy

1.85

Held after the NSE (September 2026). Earlier A$1.75 after the placement.

Ord Minnett (Tom Godfrey)

Positive

1.80

Raised 20% after the Pro Medicus HoA (June 2026). Ord Minnett was lead manager on the 2024 placement.

Bell Potter

——

FY2026 EPS forecast −1.6c; FY2027 −1.9c (July 2026)

Shaw and Partners

——

FY2026 EPS forecast −2.1c; FY2027 −1.4c

Evolution Capital

Coverage noted

—

Referenced by Stockhead

FNArena consensus

—1.683

July 2026, before the NSE

“—” = not publicly disclosed.

Catalyst / Monitorable Details

Catalyst / monitorableExpected timingWhy it matters

Disclosure of NSE reasons and the chosen pathway (appeal, Ombudsman or new 510(k))

Q4 CY2026

Sets the HF timeline

Q1 FY2027 Appendix 4C (September quarter)

Late October 2026

First post-raise burn, receipts and utilisation

AGM

Q4 CY2026

Remuneration report vote after the bonus decisions

Pro Medicus binding reseller agreement and note funding

Q4 CY2026 to H1 CY2027

Unlocks the A$10m tranche and the US channel

Conversion of any of the three enterprise proposals

H1 CY2027

First material contracted revenue

CMS CY2027 hospital outpatient final rule (New Technology APC for software)

Around November 2026

Reimbursement pathway

JACC: Heart Failure publication of HF validation

Not dated

Evidence for regulators and payers

Mayo cardio-oncology results

First half of CY2027

Pipeline validation

Director LTI tranche (a), FDA HF by 31 December 2026

31 December 2026

Likely lapses; governance signal

Use of placement proceeds for M&A

Ongoing

Capital allocation discipline

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesEducation / age

Dustin Haines

Chief Executive Officer (US-based)

Since 10 January 2025

VP and GM, Gilead Sciences (Asia, Middle East, Turkey and Russia); Chief Commercial Officer, Next Science (ASX: NXS); over a decade at ViiV Healthcare and GSK across Japan, Europe and the US

Education and age not disclosed

Matthew Dodds

Chief Financial Officer

Since 24 June 2026

Senior roles at LivaNova PLC and Johnson & Johnson Medical Devices; over 20 years as a Wall Street medtech analyst

—

Nick Lubbers

US President and General Manager

Appointed during FY2026 (date not disclosed)

Over 15 years in cardiovascular commercial roles at Boston Scientific, HeartFlow and Tempus

—

Deon Strydom

Chief Commercial Officer (as quoted in November 2024)

——

Not disclosed; current status unconfirmed

Jessamyn Lyons

Company Secretary

Since 22 October 2021

Macquarie Bank, UBS (London), Patersons Securities

BCom (UWA); FGIA

“—” = not publicly disclosed.

Board of Directors

NameRoleAppointedBackgroundOther listed boards (FY2026 AR)

Andrew Grover

Executive Chair. Interim Managing Director until January 2025.

24 May 2019

Over 30 years as an entrepreneur and investor; businesses featured in BRW Fast 100 and Deloitte Fast 50; former CEO of a recruitment firm acquired by an ASX company

Chair of Nutritional Growth Solutions (NGS); director of Spacetalk (SPA) and Findi (FND)

Steven Formica

Non-executive director

2 July 2018

Over 30 years in private businesses (manufacturing, construction, property, resources)

Multiple resources company chair and director roles (FY2025 AR: Ragnar Metals, Kaiser Reef, Albion Resources, Bindi Metals, Great Northern Minerals)

Stephen Picton

Non-executive director

20 October 2021

BSc; MSc (London Business School); Sloan Fellow (1993); Chartered Engineer; senior roles at BT and AAPT; founded gotalk; relaunched LBNCo

Comms Group (CCG)

Kenneth Nelson

Non-executive director (US-based)

11 December 2024

25-year cardiac digital-health executive: BioTelemetry (Global VP Sales), iRhythm (VP Sales and Marketing), Bardy Diagnostics (CCO), Guidant/Boston Scientific, Biotronik; founder of Nelson Jennings Ventures

HeartBeam (NASDAQ: BEAT), Acarix (Nasdaq Stockholm), plus private boards

Simon Tolhurst (former)

Non-executive director

1 June 2023 to 11 December 2024

Former HWL Ebsworth partner

Not applicable

Directors' Remuneration

KMPCash salary and fees (AUD)Non-monetary (AUD)Super (AUD)Share-based payments (AUD)Total FY2026 (AUD)Total FY2025 (AUD)

Andrew Grover (Executive Chair)

345,700028,8001,453,7491,828,249949,266

Dustin Haines (CEO)

589,50655,04501,013,9331,658,484741,698

Steven Formica (NED)

66,00007,920804,404878,324394,537

Kenneth Nelson (NED)

132,59100318,290450,881364,921

Stephen Picton (NED)

54,05406,486060,54061,277

Matthew Dodds (CFO, 24–30 June 2026)

8,9323,9120012,8440

Total KMP

1196783

58957

43206

3590376

4889322

2544699

Major Shareholders

HolderSharesApprox. % of ~740.6mBasis

Steven Formica (and associates)

33,016,6674.5

FY2026 AR, at 30 June 2026

A22 Pty Ltd (controlled by Mr Grover's spouse; Grover states no relevant interest)

32,500,0004.4

FY2026 AR

Stephen Picton (and associates)

23,014,8543.1

FY2026 AR

Stevsand Investment Pty Ltd

—

2.95 (at November 2024, pre-dilution)

Biotech Daily, November 2024

Bellco Investment Pty Ltd (Northland super fund)

—

2.59 (at November 2024, pre-dilution)

Biotech Daily, November 2024

Pro Medicus Limited

0 ordinary shares; holder of convertible notes (A$10m initial, if issued)

Potential

FY2026 AR

July 2026 placement institutions (unnamed domestic and international healthcare and technology funds)

75862069 in aggregate

10.2 in aggregate

ASX, 1 July 2026

Targets & Commitments

InitiativeDateTypeStatus

CEO hire (Haines) and US leadership build-out

January 2025 onward

Transformation

Complete; CFO added June 2026

OTCQB listing (ECHQF)

April 2025

Capital markets / US investor access

Live

BIDMC flagship integration and health-economics study

March 2025 onward

Commercial and evidence

Interim analysis shows statistically significant gains in utilisation and confidence

Mayo Validate HF study, 510(k) submission

July–December 2025

Regulatory

NSE received September 2026

Category III CPT application

June 2025 resubmission; September 2025 panel

Reimbursement

Rejected October 2025; engagement continues

10 new patent applications and 4 trademarks

March quarter 2026

Intellectual property

Filed

Expanded Mayo agreement (HF resale, 6-year term)

March 2026

Distribution

Contingent on FDA clearance

Mount Sinai deployment

April 2026

Commercial

Live

EchoSolv VIEW, SHADOW and third installation pathway

June quarter 2026

Go-to-market

Live; three enterprise proposals

Mayo cardio-oncology research

June 2026

Pipeline

Results expected first half of CY2027

Pro Medicus HoA and convertible note agreement

June and August 2026

Strategic partnership and funding

Notes documented; reseller agreement pending

Advara HeartCare data licence

June/July 2026

Data

Executed

A$110m placement

July 2026

Capital

Completed

HF regulatory remediation (appeal, Ombudsman or new 510(k))

September 2026 onward

Regulatory

In progress

Competitive Landscape

Key Competitors

CompetitorSegment overlapProductOwnershipRevenue (relevant)Relative positioning vs Echo IQ

Ultromics (UK)

Heart failure (HFpEF), cardiac amyloidosis

EchoGo HF, EchoGo Amyloidosis (image-based echo AI; FDA-cleared HF product)

Private, venture-backed

—

Most direct HF competitor. Image-based rather than measurement-based. Already holds HF clearance, a head start Echo IQ lost in September 2026.

Us2.ai (Singapore)

Echo automation and measurements; HF

Automated echo analysis

Private

—

Automates the measurements Echo IQ consumes. Could move into disease scoring.

iCardio.ai (US)

Echo AI

Echo interpretation AI

Private

—

Emerging competitor

GE HealthCare (incl. Caption Health)

Echo hardware with embedded AI

Vivid ultrasound with AI tools

Public (NASDAQ: GEHC)

Multi-billion company-wide; echo AI not segmented

Can bundle AI natively at acquisition

Philips (incl. DiA Imaging Analysis)

Echo hardware and AI

EPIQ/Affiniti with AI quantification

Public (Euronext: PHIA)

Multi-billion; not segmented

Bundling threat

Siemens Healthineers

Echo hardware and AI

Acuson with AI

Public

Multi-billion; not segmented

Bundling threat

Anumana (US)

Heart-failure detection (low EF via ECG)

ECG-AI

Private

—

Different modality, same clinical goal of earlier HF detection

Eko Health (US)

Valve disease and low EF screening

AI stethoscope

Private

—

Upstream screening alternative (murmur/AS detection)

Viz.ai (US)

Cardiovascular care coordination (e.g. HCM)

Viz HCM and care-pathway AI

Private

—

Competes for health-system "cardio AI" budgets and workflow

Tempus (US)

Cardiology AI (ECG-based)

Tempus ECG algorithms

Public (NASDAQ: TEM)

Not segmented

Competes for cardiology data-AI mindshare

HeartFlow (US)

Cardiac AI (CT-FFR)

FFRct / Plaque Analysis

Public

—

Adjacent. Benchmark for the reimbursement-led AI scaling Echo IQ aims to copy (US President Lubbers is a HeartFlow alumnus).

“—” = not publicly disclosed.

Competitor Detail

MetricEcho IQ (FY2026)

Revenue

A$0.09m

Revenue growth

−9.6%

Net margin

−20,258%

FDA-cleared echo AI indications

1 (AS)

Recent Developments

--

Company Snapshot

2,590,000

Employees

2010

Founded

West Perth, Australia

Headquarters

SWOT Analysis

Strengths

  • FDA-cleared flagship product. EchoSolv AS received 510(k) clearance in October 2024, the company's first US-marketable product (FY2025 AR).
  • Top-tier reference sites. Deployments at Mount Sinai (ranked 2nd in the US for cardiology per US News 2025–26, as cited in the FY2026 AR) and BIDMC (about 30,000 echos a year).
  • Strong balance sheet. More than A$105m of cash in July 2026 after the A$110m placement, with zero debt (Smallcaps; FY2026 AR).
  • Data moat. Exclusive NEDA access (A$4.16m intangible, 12 years remaining) plus the Advara licence of up to one million studies.
  • Strategic validation. Pro Medicus committed up to A$20m and proposed a reseller role. Mayo's expanded agreement covers 80+ partner hospitals over a potential six years.
  • Strong clinical evidence. HF sensitivity of 99.5% on 17,000 independent echos (Mayo). AS sensitivity of 98% in the BIDMC Medicare cohort (JACC Advances).

Weaknesses

  • Negligible revenue. A$91.6k in FY2026, with nil customer cash receipts (FY2026 AR cash flow statement).
  • Accelerating burn. Operating cash outflow rose 62% to A$10.56m, and the FY2026 loss widened 40% to A$18.57m.
  • Heavy share-based pay. About A$6.2m a year in FY2025–FY2026, roughly one-third of the loss, which dilutes shareholders.
  • Governance gaps. An executive chair sits on the audit and remuneration committees, the board has no female members, and the Chair's executive/non-executive status is described inconsistently.
  • Weak commercial conversion. The US$2m revenue hurdle for 31 December 2025 was missed. Only three contracts were closed-won by March 2026.
  • No reimbursement code. The Category III CPT application was rejected in October 2025. Reliance on Miscellaneous Code 93799 makes payment uncertain.

Opportunities

  • HF clearance via remediation. The company has identified appeal, Ombudsman and new-510(k) routes (17 September 2026 update). The HF market costs about US$60bn a year.
  • New reimbursement route. A New Technology APC under the proposed CMS CY2027 hospital outpatient rule.
  • Enterprise contracts. Three enterprise proposals covering more than 300 hospitals, generated through VIEW and SHADOW.
  • Pro Medicus channel. Visage 7 Cardiology reaches leading US academic centres.
  • Pipeline expansion. Pulmonary hypertension, hypertrophic cardiomyopathy, mitral regurgitation and cardio-oncology (Mayo Arizona results expected first half of CY2027).
  • International expansion. European, UK and Australian regulatory pathways are flagged in the FY2026 outlook, and 10 international patent filings were made in the March 2026 quarter.

Threats

  • Prolonged HF delay or a new study. The FDA could require a new clinical study, delaying HF by 12 months or more. Several stakeholders depend on HF clearance: the second Pro Medicus tranche, Mayo HF distribution and director LTI tranche (a).
  • OEM bundling. GE HealthCare, Philips and Siemens Healthineers could embed AI at no incremental cost.
  • Valuation volatility. Shares fell 48% in one day on 9 September 2026 and about 65% from the June high, which could constrain future raises and staff retention.
  • Partner execution risk. The Pro Medicus reseller agreement is not yet binding. The FY2026 AR states the arrangements remain subject to definitive agreements and conditions.
  • Reimbursement policy risk. The CMS proposal is not final, and AMA CPT framework changes are uncertain.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
3 Apr 2025Mayo Clinic Platform agreement for HF validation and network useGateway to HF regulatory submission
16 Apr 2025OTCQB listing (ECHQF)US investor access
May 2025A$17.3m placement at A$0.30Funded US commercialisation and HF regulatory work
Jun 2025Category III CPT resubmissionReimbursement pathway
1 Jul 2025Mayo Validate HF study commencedFinal clinical step before 510(k)
8 Jul 2025General meeting approved 13m director performance rights and 8m optionsGovernance and dilution
10 Jul 2025SARC MedIQ reseller agreementChannel to 300+ facilities
Sep Q 2025Dr Philippe Genereux appointed strategic adviserStructural-heart key opinion leader credibility
25 Sep 2025FY2025 Annual Report: loss A$13.26m; net assets A$22.76mBaseline
6 Oct 2025AMA rejected the Category III CPT code for EchoSolv ASReimbursement setback; share price about A$0.205
Oct 2025153% increase in echos processed by integrated US customers; 90,000+ echos analysed globallyAdoption signal
30 Oct 2025Q1 FY2026 quarterly: operating cash outflow A$2.51m; cash A$15.9mFunding visibility
Nov 2025AHA Scientific Sessions aortic stenosis dataClinical visibility
24 Nov 2025Mayo HF validation met primary endpoint (sensitivity 99.5%, specificity ~91%)Major de-risking event at the time
15 Dec 2025FDA 510(k) for EchoSolv HF lodgedRegulatory catalyst set
Feb 2026H1 FY2026 results: loss A$8.66m; liquidity A$13.21mHigher burn
Mar Q 202610 patent filings; JACC: HF submission; 9,220 echos (+131% QoQ); 3 contracts closed-wonIntellectual property and adoption
Mar 2026S&P Dow Jones Indices March 2026 quarterly rebalance referenced in EIQ announcementsPossible index inclusion; specific index unconfirmed in documents reviewed
24 Mar 2026Expanded Mayo Clinic HF agreement (80+ partner hospitals, 6-year term)Shares +17.1%
28 Apr 2026EchoSolv AS deployed at Mount Sinai Health SystemReference site; shares −14% on the day (to A$0.99)
7 May 2026Investor update on commercial milestonesCommunication
May 2026A$763k R&D tax incentive receivedNon-dilutive funding
Jun 2026Mayo cardio-oncology collaboration; Dr Vinod Thourani and Kyle Fortman added as advisersPipeline and key opinion leaders
24 Jun 2026Matthew Dodds appointed CFOInstitutional-grade finance leadership
25 Jun 2026Binding HoA with Pro Medicus (up to A$20m, US reseller)Shares +30%; record intraday high A$1.875; Ord Minnett target raised 20% to A$1.80
1 Jul 2026About A$110m institutional placement at A$1.45Transformational balance sheet
2 Jul 2026Advara HeartCare exclusive data licence announcedData moat; shares +8%
9 Jul 2026Cash bonuses to Executive Chair (A$200k) and CEO (US$200k); base pay increasesGovernance scrutiny
27 Jul 2026Q4 FY2026 quarterly: 10,200+ echos; 70+ hospital pipeline; 3 enterprise proposals (300+ hospitals); cash A$8.7m before placement; no customer revenue in FY2026Utilisation up, revenue lagging; shares fell on release
Jul 2026CMS proposed CY2027 hospital outpatient rule with an interim payment pathway for SaaS-type medical softwarePotential reimbursement tailwind
17 Aug 2026Pro Medicus convertible note agreement executedFunding framework documented
28 Aug 2026FY2026 results: loss A$18.57m (+40%); revenue A$91.6kShares −7.6%
~7 Sep 2026Trading halt requested ahead of a regulatory announcementSignalled a material FDA event
9 Sep 2026FDA Not Substantially Equivalent determination for EchoSolv HFShares −48% to A$0.64 close (intraday low A$0.47) on 53m shares traded; Morgans held Speculative Buy with a A$1.85 target
17 Sep 2026Regulatory update: the company sees a "clear path"; options are administrative appeal, FDA Ombudsman review or a new 510(k); no concerns identified with core technologyShares +10%
23 Sep 2026Shares around A$0.66, about 65% below the high; the market noted the absence of detailed NSE reasons and the unpublished Mayo paperInformation vacuum
24 Sep 2026Annual report lodged (InvestSMART filing log)Governance cycle; AGM expected in Q4 CY2026 (date not confirmed)

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Income Statement: Revenue & Gross Profit: Revenue fell from AUD 0.9 Mn in FY2022 to AUD 0.1 Mn in FY2026.
Echo IQ Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue0.90.100.10.1
Total revenue0.90.100.10.1
Australia revenue——00.10.1
United States revenue——000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.